Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Feb;35(2):256–258. doi: 10.1128/aac.35.2.256

Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

R R Muder 1, C Brennen 1, A M Goetz 1, M M Wagener 1, J D Rihs 1
PMCID: PMC244987  PMID: 2024958

Abstract

We performed a case-control study of risk factors for the acquisition of ciprofloxacin-resistant gram-negative isolates in a Veterans Affairs medical center. Sixty-five patients with resistant isolates and 50 control patients were identified. Prior fluoroquinolone use was significantly more frequent among patients with resistant isolates than it was among controls (58 versus 20%; P = 0.0001). The association with prior quinolone use was stronger in the long-term-care division (81 versus 32%; P = 0.0005) than it was in the acute-care division (29 versus 0%; P = 0.015). On multivariate analysis, prior receipt of a fluoroquinolone was the single most significant risk factor for isolation of a ciprofloxacin-resistant gram-negative organism (P = 0.0001).

Full text

PDF
256

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjork D. T., Pelletier L. L., Tight R. R. Urinary tract infections with antibiotic resistant organisms in catheterized nursing home patients. Infect Control. 1984 Apr;5(4):173–176. doi: 10.1017/s0195941700059178. [DOI] [PubMed] [Google Scholar]
  2. Celesk R. A., Robillard N. J. Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1989 Nov;33(11):1921–1926. doi: 10.1128/aac.33.11.1921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Farber B. F., Brennen C., Puntereri A. J., Brody J. P. A prospective study of nosocomial infections in a chronic care facility. J Am Geriatr Soc. 1984 Jul;32(7):499–502. doi: 10.1111/j.1532-5415.1984.tb02234.x. [DOI] [PubMed] [Google Scholar]
  4. Garibaldi R. A., Brodine S., Matsumiya S. Infections among patients in nursing homes: policies, prevalence, problems. N Engl J Med. 1981 Sep 24;305(13):731–735. doi: 10.1056/NEJM198109243051304. [DOI] [PubMed] [Google Scholar]
  5. Garner J. S., Jarvis W. R., Emori T. G., Horan T. C., Hughes J. M. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988 Jun;16(3):128–140. doi: 10.1016/0196-6553(88)90053-3. [DOI] [PubMed] [Google Scholar]
  6. Gaynes R. P., Weinstein R. A., Chamberlin W., Kabins S. A. Antibiotic-resistant flora in nursing home patients admitted to the hospital. Arch Intern Med. 1985 Oct;145(10):1804–1807. [PubMed] [Google Scholar]
  7. Hsu C. C., Macaluso C. P., Special L., Hubble R. H. High rate of methicillin resistance of Staphylococcus aureus isolated from hospitalized nursing home patients. Arch Intern Med. 1988 Mar;148(3):569–570. [PubMed] [Google Scholar]
  8. Kresken M., Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother. 1988 Aug;32(8):1285–1288. doi: 10.1128/aac.32.8.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Masecar B. L., Celesk R. A., Robillard N. J. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Feb;34(2):281–286. doi: 10.1128/aac.34.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Price L. E., Sarubbi F. A., Jr, Rutala W. A. Infection control programs in twelve North Carolina extended care facilities. Infect Control. 1985 Nov;6(11):437–441. doi: 10.1017/s0195941700064778. [DOI] [PubMed] [Google Scholar]
  11. Robillard N. J., Scarpa A. L. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother. 1988 Apr;32(4):535–539. doi: 10.1128/aac.32.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sanders C. C., Watanakunakorn C. Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. J Infect Dis. 1986 Mar;153(3):617–619. doi: 10.1093/infdis/153.3.617. [DOI] [PubMed] [Google Scholar]
  13. Smith S. M., Eng R. H., Tecson-Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother. 1989 Feb;33(2):181–184. doi: 10.1128/aac.33.2.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Watanabe M., Kotera Y., Yosue K., Inoue M., Mitsuhashi S. In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens. Antimicrob Agents Chemother. 1990 Jan;34(1):173–175. doi: 10.1128/aac.34.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Zervos M. J., Terpenning M. S., Schaberg D. R., Therasse P. M., Medendorp S. V., Kauffman C. A. High-level aminoglycoside-resistant enterococci. Colonization of nursing home and acute care hospital patients. Arch Intern Med. 1987 Sep;147(9):1591–1594. doi: 10.1001/archinte.147.9.1591. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES